Cyclacel pharmaceuticals reports fadraciclib phase 1 data suggesting efficacy against tumors with cdkn2a, cdkn2b and mtap deletions

- patient pharmacodynamic data show decrease in cdkn2a, cdkn2b, and prmt5 protein levels - - a squamous non-small cell lung cancer patient with cdkn2b deletion achieved marked tumor shrinkage after one cycle - - retrospective analysis identified cdkn2a, cdkn2b and/or mtap deletions in four patients previously dosed with fadra achieving responses or stable disease - - forthcoming phase 2 study to further evaluate fadra efficacy - berkeley heights, n.j., dec. 18, 2023 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today interim results from its phase 1, dose escalation 065-101 study of fadraciclib (“fadra”) in patients with advanced solid tumors and lymphoma.
CYCC Ratings Summary
CYCC Quant Ranking